Lattice Biologics Ltd. Reports Year End 2019 Results and Q1 Preliminary Q1 2020 Revenues

BELGRADE, Mont.--(BUSINESS WIRE)--Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) announces financial results for the fiscal year end 2019 and preliminary revenues for Q1 2020.

Sales and Product Offerings

• Successfully relocated processing facility to Belgrade, Montana, resulting in reduced overhead and increased operational efficiencies.
• Launched new products into a higher margin dental market.
• Gross profit margin was 44.0% for the year ended September 30, 2019, compared to 46.9% for the year ended September 30, 2018.
• For the year ended September 30, 2019, sales increased 89.5% year over year, while gross profit decreased 6.2% year over year.
• Launched new products into the higher margin dental market.
• Cash from operations was $0.2 million for the year ended September 30, 2019 compared to $0.3 million for the year ended September 30, 2018.

Finance

• Successfully relocated operations to Belgrade, Montana from Scottsdale, Arizona, resulting in operational efficiencies of over $145,000 per month, year over year.
• Gross profit of $1.0 million on sales of $2.2 million for the year ended September 30, 2019 compared to $0.5 million on sales of $1.2 million for the year ended September 30, 2018.
• Incurred a net loss of $1.0 million ($0.01 per share) for the year ended September 30, 2019 compared to $1.2 million ($0.01 per share) for the year ended September 30, 2018.
• Total liabilities increased to $8.6 million from $8.4 million for September 30, 2019 and September 30, 2018, respectively.
• Current liabilities increased to $7.7 million from $7.0 million for September 30, 2019 and September 30, 2018, respectively.

Research and Development

• Developed room temperature AmnioBoost for dental markets.
• Re-formulated DBM putty to incorporate superior handling properties.
• Developed DBM fiber plugs for dental market

2019 Business Update:

“I am pleased to announce that the Company continues with 89.5% growth throughout 2019 and a first quarter 2020 sales estimate of $690,000 - $710.000,” said Guy Cook, CEO of Lattice Biologics Ltd. “We estimate revenues to be $ 3.1-3.5 million for 2020.”

With strong distribution partners and an enhanced product line intended for dental indications, we expect sales to continue to grow throughout 2020. Operationally, the company is much more efficient and has lowered its operating and overhead costs to effectively compete in the dental market space.

As we continue to focus to higher margin product line, and to re-position the Amnioboost line for dental indications, we are confident we have turned the corner and positioned the company for profitable and continued growth.

The Company continues to make significant improvements on the balance sheet, and is working with creditors to convert certain balances to equity for working capital purposes.

Lattice Biologics maintains its commitment to honoring the gift of donation by implementing a strong quality control environment for the recovery and processing of donors. The Company has significantly increased its processing efficiencies, and has substantial inventory reserves to meet customer demand.

As indicated below, the Company continues efforts to diversify the sales mix across the new higher margin product lines added in prior years.

Year End Financial Results (all figures denoted in USD):

The product launches have been well received by our clients and the Company continues to replace unprofitable legacy contracts and focus on the newer higher margin products. Lattice Biologics’ total revenue was $2,188,631 in the year ended September 30, 2019 compared to $1,155,041 for the year ended September 30, 2018, an increase of 89.5%, as shown in the following quarter sales table:

	Sep-30			Jun-30			Mar-31		Dec-31		Sep-30			Jun-30			Mar-31			Dec-31
		2019			2019			2019		2018		2018			2018			2018			2017
Revenue	$	522,263		$	447,973		$	751,084	$	467,311	$	278,459		$	190,524		$	323,921		$	362,137
Cost of sales		621,202			287,484			172,788		144,849		271,398			115,588			102,963			123,938
Gross profit		(98,939	)		160,489			578,296		322,462		7,061			74,936			220,958			238,199
Operating costs (i)		396,053			331,795			344,397		283,062		567,058			434,925			382,764			336,332
EBITDA (ii)		(480,280	)		(156,771	)		246,648		52,149		(546,873	)		(346,865	)		(148,682	)		(85,509	)

The following table sets out selected unaudited financial information, prepared in accordance with IFRS. The information contained herein is drawn from interim financial statements of the Company for each of the following quarterly periods ending:

	Sep-30			Jun-30			Mar-31			Dec-31			Sep-30			Jun-30			Mar-31			Dec-31
		2019			2019			2019			2018			2018			2018			2018			2017
ADM dermis	$	-	0%	$	-	0%	$	-	0%	$	-	0%	$	-	0%	$	18,500	10%	$	68,600	21%	$	73,399	20%
DBM putty		-	0%		-	0%		-	0%		-	0%		-	0%		8,300	4%		10,650	3%		18,749	5%
Bone scaffold		508,458	97%		432,400	97%		725,435	97%		453,111	97%		222,333	80%		119,935	63%		204,028	63%		212,972	59%
Other		13,805	3%		15,573	3%		25,649	3%		14,200	3%		56,126	20%		43,789	23%		40,643	13%		57,017	16%
Total revenue	$	522,263	100%	$	447,973	100%	$	751,084	100%	$	467,311	100%	$	278,459	100%	$	190,524	100%	$	323,921	100%	$	362,137	100%

Certain adjustments have been made to the quarterly information for the first three quarters of the fiscal year ended September 30, 2016, as compared to data contained in the quarterly filings for such quarters. These changes relate to certain adjustments for cost of sales and operating costs that were not recognized until the fourth quarter of such fiscal year.

(i) Operating costs are defined as all general and administrative costs, professional fees, rent, salaries and benefits, sales and marketing, and utilities expenses.

(ii) EBITDA is defined as gross profit less operating costs (as defined above).

About Lattice Biologics Ltd.:

Lattice Biologics is traded on the TSX-V under the symbol: LBL. The Company is an emerging leader in the field of dental biologics and tissue engineering, with a focus on bone, skin, and cartilage regeneration.

Lattice Biologics develops and manufactures biologic products to domestic and international markets. The Company’s products are used in a variety of surgical applications.

Lattice Biologics maintains its headquarters, laboratory and manufacturing facilities in Belgrade, Montana. The facility includes ISO Class 1000 clean rooms, and specialized equipment capable of crafting traditional allografts and precision specialty allografts for various clinical applications. The Lattice Biologics team includes highly trained tissue bank specialists, surgical technicians, certified sterile processing and distribution technicians, and CNC operators who maintain the highest standards of aseptic technique throughout each step of the manufacturing process. From donor acceptance to the final packaging and distribution of finished allografts, Lattice is committed to maintaining the highest standards of allograft quality, innovation, and customer satisfaction.

Lattice Biologics maintains all necessary licensures to process and sell its tissue engineered products within the U.S. and internationally. This includes Certificates to Foreign Governments from the U.S. Food and Drug Administration (FDA) and registrations for 29 countries, which allow the export of bone, tendon, meniscus, ligament, soft tissue, and cartilage products outside of the U.S.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statement on Forward-Looking Information:

Certain information contained in this news release constitutes “forward-looking statements” within the meaning of the ‘safe harbour’ provisions of Canadian securities laws. All statements herein, other than statements of historical fact, are to be considered forward looking. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “planned”, “potential”, “future”, “expected”, “could”, “possible”, “goal”, “intends”, “will” or similar expressions. Forward-looking statements in this news release include, without limitation: information pertaining to the Company’s strategy, plans, or future financial performance, such as statements with respect to the Transaction, and other statements that express management’s expectations or estimates of future performance. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Lattice to be materially different from those expressed or implied by such forward-looking statements.

Forward-looking statements are necessarily based upon a number of factors and assumptions that, while considered reasonable by management as of the date such statements are made, are inherently subject to significant business, economic and competitive uncertainties and contingencies. The factors and assumptions that could prove to be incorrect, include, but are not limited to: that market prices will be consistent with expectations, the continued availability of capital and financing, and that general economic, market and business conditions will be consistent with expectations. The forward-looking statements are not guarantees of future performance. We disclaim any obligation to update or revise any forward-looking statements, except as required by law. Readers are cautioned not to put undue reliance on these forward-looking statements.

United States Advisory: The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), and may not be offered, sold, or resold in the United States or to, or for the account of or benefit of, a U.S. Person (as such term is defined in Regulation S under the U.S. Securities Act) unless an exemption from the registration requirements of the U.S. Securities Act is available. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in the state in the United States in which such offer, solicitation or sale would be unlawful.

Subscribe to Lattice News Updates

Follow us on Twitter: @LatticeBio